| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 103 | 2024 | 144 | 26.220 |
Why?
|
| Lung Neoplasms | 32 | 2023 | 358 | 10.650 |
Why?
|
| Asbestos | 41 | 2024 | 55 | 9.270 |
Why?
|
| Pleural Neoplasms | 43 | 2020 | 53 | 8.580 |
Why?
|
| Ubiquitin Thiolesterase | 23 | 2023 | 52 | 8.440 |
Why?
|
| Tumor Suppressor Proteins | 26 | 2024 | 194 | 8.090 |
Why?
|
| Simian virus 40 | 26 | 2011 | 47 | 5.070 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2024 | 628 | 3.630 |
Why?
|
| Germ-Line Mutation | 10 | 2024 | 57 | 3.540 |
Why?
|
| HMGB1 Protein | 11 | 2023 | 29 | 3.530 |
Why?
|
| Melanoma | 8 | 2022 | 96 | 3.090 |
Why?
|
| Cell Transformation, Neoplastic | 14 | 2020 | 172 | 3.040 |
Why?
|
| Occupational Exposure | 11 | 2023 | 79 | 2.890 |
Why?
|
| Environmental Exposure | 12 | 2016 | 216 | 2.600 |
Why?
|
| Skin Neoplasms | 6 | 2022 | 159 | 2.390 |
Why?
|
| Humans | 133 | 2024 | 37093 | 2.110 |
Why?
|
| Zeolites | 7 | 2015 | 7 | 2.010 |
Why?
|
| Neoplasms | 12 | 2020 | 1103 | 1.930 |
Why?
|
| Uveal Neoplasms | 4 | 2020 | 9 | 1.810 |
Why?
|
| Epithelium | 10 | 2017 | 79 | 1.640 |
Why?
|
| Coronavirus | 2 | 2021 | 7 | 1.490 |
Why?
|
| Mutation | 8 | 2023 | 1095 | 1.430 |
Why?
|
| Tumor Virus Infections | 12 | 2011 | 26 | 1.310 |
Why?
|
| Asbestosis | 4 | 2020 | 6 | 1.310 |
Why?
|
| Inhalation Exposure | 3 | 2019 | 43 | 1.200 |
Why?
|
| Polyomavirus Infections | 10 | 2011 | 21 | 1.190 |
Why?
|
| Carcinogens | 10 | 2015 | 124 | 1.180 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 312 | 1.090 |
Why?
|
| Immunotherapy | 5 | 2018 | 95 | 1.080 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2024 | 213 | 1.070 |
Why?
|
| Calcium Signaling | 2 | 2024 | 101 | 1.050 |
Why?
|
| Apoptosis | 10 | 2024 | 1398 | 1.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 4 | 2008 | 13 | 0.950 |
Why?
|
| Arsenic | 2 | 2023 | 144 | 0.940 |
Why?
|
| Water Pollutants, Chemical | 2 | 2023 | 164 | 0.920 |
Why?
|
| Female | 41 | 2024 | 20969 | 0.920 |
Why?
|
| Peritoneal Neoplasms | 5 | 2016 | 16 | 0.920 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 75 | 0.920 |
Why?
|
| Incidence | 8 | 2023 | 922 | 0.910 |
Why?
|
| Mitochondria | 2 | 2017 | 487 | 0.910 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2023 | 356 | 0.900 |
Why?
|
| Stearoyl-CoA Desaturase | 2 | 2019 | 5 | 0.890 |
Why?
|
| Cell Nucleus | 4 | 2021 | 366 | 0.870 |
Why?
|
| Prognosis | 12 | 2022 | 739 | 0.870 |
Why?
|
| DNA Repair | 1 | 2024 | 188 | 0.870 |
Why?
|
| Animals | 42 | 2023 | 15081 | 0.860 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2023 | 84 | 0.830 |
Why?
|
| Histone Deacetylase 1 | 1 | 2021 | 15 | 0.820 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2015 | 31 | 0.810 |
Why?
|
| Nasopharynx | 1 | 2021 | 6 | 0.800 |
Why?
|
| Male | 37 | 2024 | 20025 | 0.800 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 28 | 0.790 |
Why?
|
| Pneumonectomy | 2 | 2019 | 7 | 0.770 |
Why?
|
| Cell Transformation, Viral | 5 | 2011 | 29 | 0.770 |
Why?
|
| Heterozygote | 4 | 2023 | 93 | 0.750 |
Why?
|
| Middle Aged | 25 | 2024 | 10129 | 0.750 |
Why?
|
| Epithelial Cells | 7 | 2020 | 384 | 0.730 |
Why?
|
| RecQ Helicases | 1 | 2020 | 35 | 0.730 |
Why?
|
| Communicable Diseases | 1 | 2021 | 45 | 0.730 |
Why?
|
| Inflammation | 6 | 2023 | 618 | 0.730 |
Why?
|
| Cell Death | 6 | 2023 | 267 | 0.720 |
Why?
|
| Aged | 24 | 2021 | 6741 | 0.710 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 68 | 0.700 |
Why?
|
| Asbestos, Crocidolite | 5 | 2020 | 8 | 0.700 |
Why?
|
| Signal Transduction | 8 | 2020 | 1908 | 0.680 |
Why?
|
| Pneumonia | 1 | 2020 | 54 | 0.680 |
Why?
|
| Achievement | 1 | 2018 | 24 | 0.650 |
Why?
|
| Bibliometrics | 1 | 2018 | 17 | 0.650 |
Why?
|
| Mice | 20 | 2023 | 5913 | 0.650 |
Why?
|
| Neurofibromin 2 | 2 | 2015 | 3 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 68 | 0.640 |
Why?
|
| Cullin Proteins | 2 | 2015 | 12 | 0.640 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 76 | 0.630 |
Why?
|
| Repressor Proteins | 5 | 2018 | 249 | 0.630 |
Why?
|
| Immunohistochemistry | 12 | 2016 | 893 | 0.620 |
Why?
|
| Reward | 1 | 2018 | 79 | 0.610 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 9 | 0.600 |
Why?
|
| Research Personnel | 1 | 2018 | 155 | 0.590 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 128 | 0.580 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 9 | 0.580 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 17 | 0.580 |
Why?
|
| Cytoplasm | 1 | 2017 | 143 | 0.570 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2015 | 32 | 0.570 |
Why?
|
| Cell Movement | 5 | 2017 | 571 | 0.570 |
Why?
|
| Cancer Vaccines | 2 | 2015 | 21 | 0.560 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 105 | 0.560 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 56 | 0.560 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2016 | 1 | 0.550 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2016 | 1 | 0.550 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 4 | 0.550 |
Why?
|
| Neoplasms, Second Primary | 2 | 2014 | 13 | 0.550 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 92 | 0.540 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2015 | 2 | 0.540 |
Why?
|
| Membrane Proteins | 3 | 2012 | 517 | 0.530 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 39 | 0.520 |
Why?
|
| Gene Silencing | 4 | 2016 | 151 | 0.510 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 88 | 0.510 |
Why?
|
| Particulate Matter | 1 | 2015 | 51 | 0.510 |
Why?
|
| Iron | 2 | 2022 | 225 | 0.500 |
Why?
|
| Calcium | 1 | 2017 | 480 | 0.480 |
Why?
|
| Asbestos, Serpentine | 1 | 2013 | 2 | 0.470 |
Why?
|
| United States | 9 | 2022 | 4223 | 0.460 |
Why?
|
| Cells, Cultured | 10 | 2020 | 1518 | 0.450 |
Why?
|
| Hazardous Substances | 1 | 2013 | 18 | 0.450 |
Why?
|
| Turkey | 6 | 2015 | 22 | 0.440 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 290 | 0.440 |
Why?
|
| Cell Line, Tumor | 14 | 2018 | 2231 | 0.430 |
Why?
|
| Genomic Instability | 2 | 2024 | 38 | 0.430 |
Why?
|
| Receptors, Cell Surface | 2 | 2003 | 144 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 807 | 0.420 |
Why?
|
| Pedigree | 4 | 2015 | 79 | 0.380 |
Why?
|
| DNA, Viral | 4 | 2011 | 304 | 0.380 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 214 | 0.360 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 803 | 0.350 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2009 | 5 | 0.350 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 217 | 0.350 |
Why?
|
| Genes, Tumor Suppressor | 6 | 2005 | 63 | 0.340 |
Why?
|
| Consensus | 3 | 2018 | 45 | 0.340 |
Why?
|
| Fibroblasts | 2 | 2024 | 272 | 0.340 |
Why?
|
| Protein Binding | 3 | 2021 | 972 | 0.340 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 935 | 0.340 |
Why?
|
| Ubiquitin | 2 | 2021 | 78 | 0.340 |
Why?
|
| Aged, 80 and over | 11 | 2016 | 2379 | 0.330 |
Why?
|
| Drug Contamination | 2 | 2005 | 7 | 0.320 |
Why?
|
| Transcription Factors | 2 | 2003 | 681 | 0.310 |
Why?
|
| Biopsy | 3 | 2016 | 164 | 0.310 |
Why?
|
| Adult | 15 | 2020 | 11712 | 0.310 |
Why?
|
| Neoplasm Staging | 8 | 2017 | 275 | 0.300 |
Why?
|
| Oncogenes | 2 | 2004 | 43 | 0.300 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 70 | 0.300 |
Why?
|
| Brain Neoplasms | 2 | 2011 | 111 | 0.300 |
Why?
|
| NF-kappa B | 2 | 2009 | 339 | 0.290 |
Why?
|
| Polymerase Chain Reaction | 8 | 2010 | 448 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2021 | 623 | 0.280 |
Why?
|
| China | 2 | 2017 | 196 | 0.280 |
Why?
|
| Alleles | 4 | 2016 | 321 | 0.280 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 16 | 0.280 |
Why?
|
| Environmental Pollutants | 1 | 2009 | 179 | 0.280 |
Why?
|
| Cell Proliferation | 6 | 2017 | 1198 | 0.270 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2005 | 3 | 0.270 |
Why?
|
| Osteopontin | 4 | 2016 | 36 | 0.270 |
Why?
|
| Cohort Studies | 5 | 2014 | 1492 | 0.270 |
Why?
|
| Mice, Inbred BALB C | 5 | 2017 | 661 | 0.260 |
Why?
|
| DNA Damage | 2 | 2018 | 352 | 0.260 |
Why?
|
| Telomerase | 2 | 2003 | 44 | 0.260 |
Why?
|
| Vidarabine | 1 | 2005 | 1 | 0.260 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2005 | 1 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 6 | 2017 | 502 | 0.250 |
Why?
|
| Pleura | 2 | 2019 | 5 | 0.250 |
Why?
|
| Sex Factors | 3 | 2016 | 898 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2011 | 103 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2011 | 99 | 0.250 |
Why?
|
| Mass Screening | 1 | 2009 | 462 | 0.250 |
Why?
|
| Keratins | 1 | 2004 | 25 | 0.250 |
Why?
|
| Sarcoma | 1 | 2004 | 10 | 0.250 |
Why?
|
| Environmental Monitoring | 2 | 2023 | 192 | 0.250 |
Why?
|
| Genome, Human | 2 | 2016 | 135 | 0.240 |
Why?
|
| Receptors, Growth Factor | 1 | 2003 | 12 | 0.230 |
Why?
|
| BK Virus | 1 | 2003 | 5 | 0.230 |
Why?
|
| JC Virus | 1 | 2003 | 24 | 0.230 |
Why?
|
| RNA, Messenger | 5 | 2016 | 1207 | 0.230 |
Why?
|
| Europe | 2 | 2019 | 101 | 0.230 |
Why?
|
| Age Factors | 3 | 2016 | 1033 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2016 | 753 | 0.230 |
Why?
|
| Cricetinae | 3 | 2010 | 238 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 251 | 0.220 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 148 | 0.220 |
Why?
|
| Sarcoma, Synovial | 1 | 2002 | 1 | 0.220 |
Why?
|
| Nevada | 3 | 2022 | 6 | 0.220 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 562 | 0.220 |
Why?
|
| Gene Expression Profiling | 4 | 2013 | 626 | 0.220 |
Why?
|
| Caspases | 1 | 2023 | 147 | 0.220 |
Why?
|
| Macrophages | 2 | 2020 | 439 | 0.220 |
Why?
|
| SEER Program | 2 | 2014 | 91 | 0.210 |
Why?
|
| Uranium | 1 | 2022 | 21 | 0.210 |
Why?
|
| Poliovirus Vaccines | 1 | 2002 | 2 | 0.210 |
Why?
|
| Cocarcinogenesis | 3 | 2008 | 7 | 0.200 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2021 | 6 | 0.200 |
Why?
|
| Doxorubicin | 3 | 2010 | 84 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 239 | 0.200 |
Why?
|
| Fatal Outcome | 1 | 2021 | 40 | 0.200 |
Why?
|
| Cell Line, Transformed | 4 | 2008 | 91 | 0.200 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 80 | 0.200 |
Why?
|
| Case-Control Studies | 6 | 2016 | 1130 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 53 | 0.200 |
Why?
|
| Endotoxemia | 1 | 2020 | 5 | 0.190 |
Why?
|
| Cell Line | 4 | 2018 | 1354 | 0.190 |
Why?
|
| Young Adult | 6 | 2016 | 4268 | 0.180 |
Why?
|
| Computers | 1 | 2020 | 35 | 0.180 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2020 | 67 | 0.180 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 251 | 0.180 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2020 | 48 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 974 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 70 | 0.170 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 20 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 204 | 0.170 |
Why?
|
| Autophagy | 1 | 2020 | 116 | 0.170 |
Why?
|
| Family | 1 | 2020 | 173 | 0.170 |
Why?
|
| International Cooperation | 1 | 2019 | 46 | 0.170 |
Why?
|
| Australia | 1 | 2019 | 76 | 0.170 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 149 | 0.170 |
Why?
|
| Pleural Effusion, Malignant | 3 | 2012 | 6 | 0.160 |
Why?
|
| Mesocricetus | 2 | 2010 | 54 | 0.160 |
Why?
|
| Efficiency | 1 | 2018 | 16 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2017 | 259 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 119 | 0.160 |
Why?
|
| Professional Competence | 1 | 2018 | 40 | 0.160 |
Why?
|
| Toll-Like Receptors | 1 | 2018 | 51 | 0.160 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 60 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 111 | 0.160 |
Why?
|
| Quality of Life | 1 | 2022 | 481 | 0.150 |
Why?
|
| Pyruvates | 1 | 2017 | 6 | 0.150 |
Why?
|
| Protein Stability | 1 | 2017 | 45 | 0.150 |
Why?
|
| Asthma | 1 | 2021 | 380 | 0.150 |
Why?
|
| Cell Survival | 2 | 2017 | 864 | 0.150 |
Why?
|
| Disease Progression | 6 | 2014 | 601 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2008 | 515 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 28 | 0.140 |
Why?
|
| Germ Cells | 1 | 2017 | 73 | 0.140 |
Why?
|
| Drosophila Proteins | 1 | 2018 | 171 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 336 | 0.140 |
Why?
|
| Membrane Glycoproteins | 2 | 2009 | 211 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 333 | 0.140 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 12 | 0.140 |
Why?
|
| Integrin alpha5 | 1 | 2016 | 2 | 0.140 |
Why?
|
| Multigene Family | 1 | 2016 | 106 | 0.140 |
Why?
|
| Down-Regulation | 2 | 2009 | 435 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 8 | 0.140 |
Why?
|
| Survival Rate | 2 | 2014 | 311 | 0.140 |
Why?
|
| Magnesium Compounds | 1 | 2016 | 2 | 0.140 |
Why?
|
| Silicon Compounds | 1 | 2016 | 6 | 0.140 |
Why?
|
| Genealogy and Heraldry | 1 | 2015 | 5 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2016 | 2026 | 0.140 |
Why?
|
| Skin | 1 | 2017 | 174 | 0.140 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 67 | 0.140 |
Why?
|
| Germany | 1 | 2015 | 24 | 0.140 |
Why?
|
| Molybdenum | 2 | 2022 | 14 | 0.140 |
Why?
|
| Cytokines | 4 | 2020 | 602 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1369 | 0.130 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2015 | 18 | 0.130 |
Why?
|
| RNA, Small Interfering | 4 | 2018 | 409 | 0.130 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 90 | 0.130 |
Why?
|
| Oregon | 1 | 2015 | 43 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 159 | 0.130 |
Why?
|
| Geology | 1 | 2015 | 6 | 0.130 |
Why?
|
| Weather | 1 | 2015 | 8 | 0.130 |
Why?
|
| Interferon-gamma | 2 | 2015 | 250 | 0.130 |
Why?
|
| Proteomics | 2 | 2020 | 325 | 0.130 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 142 | 0.130 |
Why?
|
| New York | 1 | 2015 | 71 | 0.130 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2015 | 88 | 0.120 |
Why?
|
| Cell Adhesion | 2 | 2012 | 212 | 0.120 |
Why?
|
| Genome, Viral | 2 | 2006 | 109 | 0.120 |
Why?
|
| Cell Shape | 1 | 2013 | 35 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 126 | 0.120 |
Why?
|
| Risk Factors | 3 | 2011 | 3562 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2012 | 448 | 0.120 |
Why?
|
| Blotting, Southern | 2 | 2005 | 69 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2010 | 44 | 0.110 |
Why?
|
| Micronutrients | 1 | 2014 | 44 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 93 | 0.110 |
Why?
|
| beta Catenin | 1 | 2013 | 48 | 0.110 |
Why?
|
| Receptor, Notch1 | 2 | 2003 | 17 | 0.110 |
Why?
|
| Fowlpox virus | 1 | 2013 | 2 | 0.110 |
Why?
|
| Disease Models, Animal | 5 | 2017 | 1371 | 0.110 |
Why?
|
| Cadherins | 1 | 2013 | 90 | 0.110 |
Why?
|
| Syndrome | 1 | 2013 | 74 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2013 | 67 | 0.110 |
Why?
|
| Disease Susceptibility | 2 | 2003 | 97 | 0.110 |
Why?
|
| Spleen | 1 | 2013 | 199 | 0.110 |
Why?
|
| Mice, SCID | 4 | 2017 | 150 | 0.100 |
Why?
|
| Models, Biological | 2 | 2008 | 677 | 0.100 |
Why?
|
| North Dakota | 1 | 2011 | 1 | 0.100 |
Why?
|
| Selenium | 1 | 2014 | 148 | 0.100 |
Why?
|
| Transportation | 1 | 2011 | 26 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 1609 | 0.100 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2011 | 11 | 0.100 |
Why?
|
| Gene Expression Regulation | 3 | 2013 | 1015 | 0.100 |
Why?
|
| Blotting, Western | 5 | 2014 | 859 | 0.100 |
Why?
|
| Vaccination | 1 | 2013 | 288 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2011 | 90 | 0.090 |
Why?
|
| HMGB Proteins | 1 | 2010 | 1 | 0.090 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2010 | 4 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 578 | 0.090 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cells | 1 | 2010 | 9 | 0.090 |
Why?
|
| Biological Therapy | 1 | 2010 | 1 | 0.090 |
Why?
|
| Family Health | 2 | 2008 | 56 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2014 | 444 | 0.090 |
Why?
|
| Air Pollutants | 1 | 2011 | 94 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 82 | 0.090 |
Why?
|
| DNA Methylation | 2 | 2005 | 325 | 0.090 |
Why?
|
| Necrosis | 1 | 2010 | 49 | 0.090 |
Why?
|
| Lectins | 2 | 2012 | 20 | 0.090 |
Why?
|
| Cell Cycle | 2 | 2018 | 326 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2010 | 78 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2007 | 82 | 0.090 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2009 | 54 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 190 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 123 | 0.080 |
Why?
|
| RNA, Antisense | 1 | 2008 | 17 | 0.080 |
Why?
|
| Blotting, Northern | 1 | 2008 | 150 | 0.080 |
Why?
|
| Transfection | 2 | 2010 | 523 | 0.080 |
Why?
|
| Virus Integration | 1 | 2008 | 58 | 0.080 |
Why?
|
| Ribonucleases | 1 | 2008 | 30 | 0.080 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 19 | 0.080 |
Why?
|
| Capsid Proteins | 1 | 2008 | 67 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 41 | 0.080 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2008 | 25 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 59 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2008 | 26 | 0.080 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2007 | 4 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 15 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 400 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 461 | 0.080 |
Why?
|
| Patient Selection | 1 | 2009 | 164 | 0.080 |
Why?
|
| Compensation and Redress | 1 | 2007 | 3 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 182 | 0.070 |
Why?
|
| Public Health Administration | 1 | 2007 | 26 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2009 | 305 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 474 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Metaphase | 1 | 2006 | 7 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2006 | 21 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 35 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 515 | 0.070 |
Why?
|
| Cross Reactions | 1 | 2006 | 83 | 0.070 |
Why?
|
| Chromosomes, Human | 1 | 2006 | 35 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 90 | 0.070 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 11 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 172 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 168 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2006 | 110 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2008 | 308 | 0.060 |
Why?
|
| Astrocytes | 1 | 2008 | 255 | 0.060 |
Why?
|
| RNA Interference | 1 | 2006 | 243 | 0.060 |
Why?
|
| Carcinogenicity Tests | 1 | 2004 | 4 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2005 | 37 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 155 | 0.060 |
Why?
|
| Pleural Effusion | 2 | 2016 | 8 | 0.060 |
Why?
|
| ROC Curve | 3 | 2012 | 138 | 0.060 |
Why?
|
| Radiography | 1 | 2004 | 72 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2007 | 928 | 0.060 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2004 | 2 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2010 | 426 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 76 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2004 | 13 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 286 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2004 | 105 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 2004 | 29 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2003 | 8 | 0.060 |
Why?
|
| Ependymoma | 1 | 2003 | 1 | 0.060 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2003 | 2 | 0.060 |
Why?
|
| Occupational Diseases | 1 | 2004 | 47 | 0.060 |
Why?
|
| Genetic Techniques | 1 | 2003 | 15 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2004 | 127 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2002 | 12 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 306 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2002 | 22 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2020 | 933 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 42 | 0.050 |
Why?
|
| Lithium | 1 | 2022 | 15 | 0.050 |
Why?
|
| Azacitidine | 1 | 2002 | 22 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2003 | 174 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 105 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2006 | 808 | 0.050 |
Why?
|
| Water Supply | 1 | 2022 | 57 | 0.050 |
Why?
|
| Cadmium | 1 | 2022 | 58 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 53 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2008 | 325 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2014 | 75 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2002 | 22 | 0.050 |
Why?
|
| Manganese | 1 | 2022 | 87 | 0.050 |
Why?
|
| Virus Replication | 1 | 2003 | 278 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2002 | 166 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2002 | 61 | 0.050 |
Why?
|
| Butadienes | 2 | 2011 | 29 | 0.050 |
Why?
|
| Nitriles | 2 | 2011 | 69 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 213 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 3483 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2003 | 513 | 0.040 |
Why?
|
| Time Factors | 3 | 2010 | 1742 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 25 | 0.040 |
Why?
|
| Adolescent | 2 | 2010 | 5363 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2018 | 15 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 25 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2018 | 61 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2018 | 131 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2018 | 176 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2018 | 189 | 0.040 |
Why?
|
| Drosophila | 1 | 2018 | 144 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 2017 | 22 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 45 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2008 | 550 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 98 | 0.030 |
Why?
|
| Brain | 1 | 2003 | 1346 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 267 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 54 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 16 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 178 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2015 | 27 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 20 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 59 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 74 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 93 | 0.030 |
Why?
|
| Immunization | 1 | 2015 | 92 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 59 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 158 | 0.030 |
Why?
|
| Hela Cells | 1 | 2015 | 366 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2015 | 113 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 190 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 236 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 431 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 89 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 1378 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2011 | 18 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 108 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 2010 | 8 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 25 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 27 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 218 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 252 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2010 | 125 | 0.020 |
Why?
|
| Neutrophils | 1 | 2010 | 131 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 61 | 0.020 |
Why?
|
| Carcinoma | 1 | 2010 | 96 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 98 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 399 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 149 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2009 | 73 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 12 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2008 | 10 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 113 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Palliative Care | 1 | 2009 | 49 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 37 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 421 | 0.020 |
Why?
|
| Rana pipiens | 1 | 2008 | 62 | 0.020 |
Why?
|
| Pleural Cavity | 1 | 2008 | 1 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2008 | 4 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 147 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 88 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 187 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 268 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 161 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 225 | 0.020 |
Why?
|
| Diet | 1 | 2014 | 801 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 190 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2010 | 317 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 441 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2004 | 93 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2005 | 455 | 0.020 |
Why?
|
| RNA, Complementary | 1 | 2004 | 9 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 131 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 186 | 0.010 |
Why?
|
| Pleural Diseases | 1 | 2002 | 3 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2002 | 32 | 0.010 |
Why?
|
| HLA Antigens | 1 | 2002 | 20 | 0.010 |
Why?
|
| CpG Islands | 1 | 2002 | 97 | 0.010 |
Why?
|
| Child | 1 | 2010 | 3131 | 0.010 |
Why?
|
| Prevalence | 1 | 2002 | 1455 | 0.010 |
Why?
|